Latest news
Professor Leroux from ETH receives the Debiopharm Life Sciences Award 2010
Debiopharm Group™ and Biocartis embark on a partnership aiming at enhancing personalized medicine
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 – A potent, first-in-class antiviral…
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent…
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of…
Debiopharm Group invests in Searchbox SA, a semantic search engine for professionals